Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates

Core Insights - Adaptive Biotechnologies reported a quarterly loss of $0.09 per share, outperforming the Zacks Consensus Estimate of a loss of $0.19, and showing improvement from a loss of $0.23 per share a year ago, resulting in an earnings surprise of +52.63% [1] - The company achieved revenues of $71.68 million for the quarter ended December 2025, which was slightly below the Zacks Consensus Estimate by 0.44%, but represented a significant increase from $47.46 million in the same quarter last year [2] - The stock has gained approximately 6.5% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] Earnings Outlook - The earnings outlook for Adaptive Biotechnologies is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.17 on revenues of $61.01 million, and for the current fiscal year at -$0.59 on revenues of $266.15 million [7] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adaptive Biotechnologies belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Guardant Health, is expected to report a quarterly loss of $0.42 per share, reflecting a year-over-year change of +32.3%, with revenues anticipated to be $279.96 million, up 38.7% from the previous year [9][10]